Kia ora Cody C

Thank you for your request for information, received by Pharmac on 30 November 2023. Your request has been received and logged. Our reference number for your request is: 2023-24-085.

As required under the Official Information Act 1982, we will respond to your request within 20 working days. You should receive a response on or before 19 January 2024.

If a large amount of information has been requested, we may need to extend this date (this is provided for in section 15A of the Act). We will advise you if such an extension is necessary.

Please feel free to contact us if you require any further assistance.

Ngâ mihi,

Katy Carlson (she/her) | Government Services Advisor
___________________________________________________________________
Te Pâtaka Whaioranga – Pharmac | PO Box 10 254 | Level 9, 40 Mercer Street, Wellington
P: 0800 660 050 |http://www.pharmac.govt.nz/

-----Original Message-----
From: Cody C <[FOI #24963 email]>
Sent: Thursday, 30 November 2023 3:47 pm
To: Web Enquiry <[email address]>
Subject: Official Information request - MoH criteria for Special Authority application of stimulant medication

[You don't often get email from [FOI #24963 email]. Learn why this is important at https://aka.ms/LearnAboutSenderIdentific... ]

Dear Pharmaceutical Management Agency,

Te Whatu Ora (formerly Canterbury DHB) advises patients that "Ministry of Health criteria for Special Authority application of stimulant medication requires a recent random urinary drug screen if stimulant medication is seen as the appropriate treatment."

Please provide these criteria in full. I was unable to locate it.

Yours faithfully,

Cody C

-------------------------------------------------------------------

This is an Official Information request made via the FYI website.

Please use this email address for all replies to this request:
[FOI #24963 email]

Is [PHARMAC request email] the wrong address for Official Information requests to Pharmaceutical Management Agency? If so, please contact us using this form:
https://fyi.org.nz/change_request/new?bo...

Disclaimer: This message and any reply that you make will be published on the internet. Our privacy and copyright policies:
https://fyi.org.nz/help/officers

If you find this service useful as an Official Information officer, please ask your web manager to link to us from your organisation's OIA or LGOIMA page.

-------------------------------------------------------------------

This e-mail message and any accompanying attachments may contain confidential information. If you are not the intended recipient, please do not read, use, disseminate, distribute or copy this message or attachments. If you have received this message in error, please notify the sender immediately and delete this message.
This e-mail message and any accompanying attachments may contain confidential information. If you are not the intended recipient, please do not read, use, disseminate, distribute or copy this message or attachments. If you have received this message in error, please notify the sender immediately and delete this message.

hide quoted sections

Kia ora Cody

Please find a response to your request attached to this email.

Ngâ mihi,

Katy Carlson (she/her) | Government Services Advisor
___________________________________________________________________
Te Pâtaka Whaioranga – Pharmac | PO Box 10 254 | Level 9, 40 Mercer Street, Wellington
P: 0800 660 050 |http://www.pharmac.govt.nz/

-----Original Message-----
From: Cody C <[FOI #24963 email]>
Sent: Thursday, 30 November 2023 3:47 pm
To: Web Enquiry <[email address]>
Subject: Official Information request - MoH criteria for Special Authority application of stimulant medication

[You don't often get email from [FOI #24963 email]. Learn why this is important at https://aka.ms/LearnAboutSenderIdentific... ]

Dear Pharmaceutical Management Agency,

Te Whatu Ora (formerly Canterbury DHB) advises patients that "Ministry of Health criteria for Special Authority application of stimulant medication requires a recent random urinary drug screen if stimulant medication is seen as the appropriate treatment."

Please provide these criteria in full. I was unable to locate it.

Yours faithfully,

Cody C

-------------------------------------------------------------------

This is an Official Information request made via the FYI website.

Please use this email address for all replies to this request:
[FOI #24963 email]

Is [PHARMAC request email] the wrong address for Official Information requests to Pharmaceutical Management Agency? If so, please contact us using this form:
https://fyi.org.nz/change_request/new?bo...

Disclaimer: This message and any reply that you make will be published on the internet. Our privacy and copyright policies:
https://fyi.org.nz/help/officers

If you find this service useful as an Official Information officer, please ask your web manager to link to us from your organisation's OIA or LGOIMA page.

-------------------------------------------------------------------

This e-mail message and any accompanying attachments may contain confidential information. If you are not the intended recipient, please do not read, use, disseminate, distribute or copy this message or attachments. If you have received this message in error, please notify the sender immediately and delete this message.
This e-mail message and any accompanying attachments may contain confidential information. If you are not the intended recipient, please do not read, use, disseminate, distribute or copy this message or attachments. If you have received this message in error, please notify the sender immediately and delete this message.

hide quoted sections